MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR): $17.60

0.05 (-0.28%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

MOR Price/Volume Stats

Current price $17.60 52-week high $17.87
Prev. close $17.65 52-week low $3.65
Day low $17.54 Volume 340,684
Day high $17.66 Avg. volume 3,341,406
50-day MA $11.73 Dividend yield N/A
200-day MA $8.29 Market Cap 2.65B

MOR Stock Price Chart Interactive Chart >


MorphoSys AG (MOR) Company Bio


MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.


MOR Latest News Stream


Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream


Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MORPHOSYS AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

Optimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is Lacking

MorphoSys AG ( ETR:MOR ) shareholders would be excited to see that the share price has had a great month, posting a 48...

Yahoo | December 18, 2023

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

PLANEGG/MUNICH, Germany, December 11, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.

Yahoo | December 11, 2023

Further weakness as MorphoSys (ETR:MOR) drops 39% this week, taking five-year losses to 84%

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

Yahoo | November 23, 2023

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

Yahoo | November 22, 2023

FSR Stock Alert: Fisker Receives Non-Compliance Notice From NYSE

Fisker stock is falling on Tuesday as FSR investors react to a non-compliance notice and the resignation of its new CAO.

William White on InvestorPlace | November 21, 2023

Read More 'MOR' Stories Here

MOR Price Returns

1-mo 92.98%
3-mo 276.87%
6-mo 122.78%
1-year 289.38%
3-year -32.10%
5-year -28.25%
YTD 77.78%
2023 176.54%
2022 -62.00%
2021 -66.76%
2020 -20.55%
2019 40.99%

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!